Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
The maximal emission wavelength and excitation wavelength of Gd-NMC-3 are 792 nm and 755 nm, respectively. The near-infrared spectrum contains both wavelengths[1]. Gd-NMC-3 can accumulate in tumor locations and functions as a bimodal imaging molecule[1]. OATPs and NTCP may internalize Gd-NMC-3 (50 μM; 24 h) into cancer cells, demonstrating a good selectivity to tumor tissues[1]. In tumors, Gd-NMC-3 (6.25-800 μM, 24 h) shows a respectable relaxation property (11.64 M/m/s) and a notable buildup of fluorescence (at the ideal dose of 100, 200 μM)[1]. Gd-NMC-3 (6.25-100 μM, 48 h) has good biocompatibility and minimal cytotoxicity[1].
|
---|---|
ln Vivo |
In LM3 orthotopic and subcutaneous tumor models, Gd-NMC-3 (20 mg/kg; iv) exhibits superior tumor targeting capabilities, high sensitivity and resolution, and real-time visual navigation to facilitate tumor resection[1].
|
Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: HepG2 and LM3: human hepatocarcinoma cell line; L02: human hepatocyte cell line Tested Concentrations: 6.25-100 μM Incubation Duration: 48 hrs (hours) Experimental Results: Resulted More than 90% cell viability maintained after 48 h. |
Animal Protocol |
Animal/Disease Models: HepG2 subcutaneous (sc) xenograft mice[1]
Doses: 20 mg/kg Route of Administration: intravenous (iv) injection; 1.5 h later dissected tumors Experimental Results: Accumulated in the tumor after injection and produced stronger fluorescence intensity in tumor tissues. Remained fluorescence signal longer than 1.5 h, and provided high-resolution images of the tumor tissues with a SNR of 4.32. Animal/Disease Models: LM3 orthotopic mice[1] Doses: 20 mg/kg Route of Administration: intravenous (iv) injection Experimental Results: diminished gradually the fluorescence intensity in LM3 orthotopic liver tumors after administration, whereas tumor-to-skin fluorescence ratios increased due to high accumulation and low clearance in tumor tissues. |
References |
[1]. Li Q, et al. Tumor-Targeting NIRF/MR Dual-Modal Molecular Imaging Probe for Surgery Navigation. Anal Chem. 2022 Aug 3.
|
Molecular Formula |
C77H116GD2N14O22S2
|
---|---|
Molecular Weight |
1968.46
|
CAS # |
2678579-76-3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.5080 mL | 2.5401 mL | 5.0801 mL | |
5 mM | 0.1016 mL | 0.5080 mL | 1.0160 mL | |
10 mM | 0.0508 mL | 0.2540 mL | 0.5080 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.